A Randomized, Open Label, Multicenter, Phase II, 2-Arm Study comparing the conventional 3 weekly schedule of Jevtana (Cabazitaxel) with a weekly regimen in patients with Metastastic Castration Resistant Prostate Cancer ConWeCab.
Phase of Trial: Phase II
Latest Information Update: 20 Apr 2018
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ConCab
- 20 Apr 2018 Primary endpoint (Relative cumulative dose of cabazitaxel at week 18) has not been met as per the results published in the European Journal of Cancer.
- 20 Apr 2018 Results published in the European Journal of Cancer
- 10 Jun 2017 Biomarkers information updated